Thoratec Corp (THOR) 40.01 $THOR
Thoratec Arrests Decline In LVAD Sales In 4th Quarter 2014, Revive-IT Is 'Dead'
Robert Honeywill - Seeking Alpha - Fri Feb 13, 8:36AM CST
This article is a continuation of my series of articles developing an investment strategy based on an area of unmet need in the health sector, viz ., long-term therapies for late stage heart failure. The significant players are Thoratec (NASDAQ:...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
CYAN: 8.72 (+0.13), STMP: 56.92 (-0.24), RENT: 58.90 (+0.39), EPRS: 7.67 (+0.67), EEFT: 53.96 (-0.91), AREX: 8.15 (+0.27), GTIM: 8.23 (+0.07), MCUR: 11.19 (-0.65), EXPE: 89.49 (-0.08), THOR: 40.01 (+0.54), CTRN: 27.20 (+0.24), DGLY: 11.50 (-0.40), DWSN: 6.89 (-0.42)
Thoratec (THOR) Upgraded From Hold to Buy
at The Street - Thu Feb 12, 12:20PM CST
Thoratec (THOR) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
THOR: 40.01 (+0.54)
Thoratec (THOR) Catches Eye: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:08AM CST
Thoratec Corp. (THOR) was a big mover last session, as the company saw its shares rise over 8% on the day.
ABMD: 60.39 (+0.46), THOR: 40.01 (+0.54)
Look for Shares of Thoratec to Potentially Pullback after Yesterday's 8.18% Rise
Comtex SmarTrend(R) - Wed Feb 11, 4:23PM CST
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $37.70 to a high of $40.25. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $36.60 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 40.01 (+0.54)
SmarTrend Watching for Potential Pullback in Shares of Thoratec After 8.18% Gain
Comtex SmarTrend(R) - Wed Feb 11, 4:23PM CST
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $37.70 to a high of $40.25. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $36.60 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 40.01 (+0.54)
Thoratec updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:55AM CST
THOR: 40.01 (+0.54)
Thoratec (THOR) Marked As A Barbarian At The Gate
at The Street - Wed Feb 11, 8:52AM CST
Trade-Ideas LLC identified Thoratec (THOR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
THOR: 40.01 (+0.54)
Thoratec Beats Q4 Earnings and Revenues, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:45AM CST
Shares of Thoratec Corp. (THOR) rallied 4.37% ($1.59) to $38.00 after the company reported impressive fourth-quarter financial numbers.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), THOR: 40.01 (+0.54), LMNX: 15.45 (+0.02)
Thoratec Corporation's (THOR) CEO Keith Grossman on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 11:08PM CST
THOR: 40.01 (+0.54)
Thoratec tops Street 4Q forecasts
Automated Insights - Tue Feb 10, 4:11PM CST
PLEASANTON, Calif. (AP) _ Thoratec Corp. (THOR) on Tuesday reported fourth-quarter net income of $11.8 million.
THOR: 40.01 (+0.54)
Thoratec (THOR) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
THOR: 40.01 (+0.54)
Thoratec beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:14PM CST
THOR: 40.01 (+0.54)
Thoratec® Reports Fourth Quarter 2014 Results
PR Newswire - Tue Feb 10, 3:02PM CST
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the fourth quarter of 2014.
THOR: 40.01 (+0.54)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Thoratec Up 20.0% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Mon Feb 09, 9:13AM CST
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 3 months, Thoratec has returned 20.03% as of today's recent price of $36.01.
THOR: 40.01 (+0.54)
Will Thoratec (THOR) Miss Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 3:42PM CST
Our proven model does not conclusively show that Thoratec Corp. (THOR) is likely to beat earnings this quarter.
ACT: 285.37 (+3.71), THOR: 40.01 (+0.54), INFI: 15.13 (+0.55), HLS: 45.01 (+0.30)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
If Thoratec's Woes Are Heartware's Gain, That's Disastrous For Both
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
An area of potential above average real growth This article is a continuation of my series looking at corporations with mechanical heart assist devices as part of a strategy for seeking above average returns by investing in heart health related...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Clinical Hold For Revive-IT Trial Raises Questions About Thoratec And Heartware
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
From the Revive-IT official web-site : REVIVE-IT is a two-part study consisting of a trial and a registry. The purpose of the REVIVE-IT study is to find out whether people with advanced heart failure who are not candidates for a heart transplant...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Thoratec Arrests Decline In LVAD Sales In 4th Quarter 2014, Revive-IT Is 'Dead'
Robert Honeywill - Seeking Alpha - Fri Feb 13, 8:36AM CST
This article is a continuation of my series of articles developing an investment strategy based on an area of unmet need in the health sector, viz ., long-term therapies for late stage heart failure. The significant players are Thoratec (NASDAQ:...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
CYAN: 8.72 (+0.13), STMP: 56.92 (-0.24), RENT: 58.90 (+0.39), EPRS: 7.67 (+0.67), EEFT: 53.96 (-0.91), AREX: 8.15 (+0.27), GTIM: 8.23 (+0.07), MCUR: 11.19 (-0.65), EXPE: 89.49 (-0.08), THOR: 40.01 (+0.54), CTRN: 27.20 (+0.24), DGLY: 11.50 (-0.40), DWSN: 6.89 (-0.42)
Thoratec (THOR) Upgraded From Hold to Buy
at The Street - Thu Feb 12, 12:20PM CST
Thoratec (THOR) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
THOR: 40.01 (+0.54)
Thoratec (THOR) Catches Eye: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:08AM CST
Thoratec Corp. (THOR) was a big mover last session, as the company saw its shares rise over 8% on the day.
ABMD: 60.39 (+0.46), THOR: 40.01 (+0.54)
Look for Shares of Thoratec to Potentially Pullback after Yesterday's 8.18% Rise
Comtex SmarTrend(R) - Wed Feb 11, 4:23PM CST
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $37.70 to a high of $40.25. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $36.60 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 40.01 (+0.54)
SmarTrend Watching for Potential Pullback in Shares of Thoratec After 8.18% Gain
Comtex SmarTrend(R) - Wed Feb 11, 4:23PM CST
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $37.70 to a high of $40.25. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high of $36.60 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 40.01 (+0.54)
Thoratec updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:55AM CST
THOR: 40.01 (+0.54)
Thoratec (THOR) Marked As A Barbarian At The Gate
at The Street - Wed Feb 11, 8:52AM CST
Trade-Ideas LLC identified Thoratec (THOR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
THOR: 40.01 (+0.54)
Thoratec Beats Q4 Earnings and Revenues, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:45AM CST
Shares of Thoratec Corp. (THOR) rallied 4.37% ($1.59) to $38.00 after the company reported impressive fourth-quarter financial numbers.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), THOR: 40.01 (+0.54), LMNX: 15.45 (+0.02)
Thoratec Corporation's (THOR) CEO Keith Grossman on Q4 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 11:08PM CST
THOR: 40.01 (+0.54)
Thoratec tops Street 4Q forecasts
Automated Insights - Tue Feb 10, 4:11PM CST
PLEASANTON, Calif. (AP) _ Thoratec Corp. (THOR) on Tuesday reported fourth-quarter net income of $11.8 million.
THOR: 40.01 (+0.54)
Thoratec (THOR) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
THOR: 40.01 (+0.54)
Thoratec beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:14PM CST
THOR: 40.01 (+0.54)
Thoratec® Reports Fourth Quarter 2014 Results
PR Newswire - Tue Feb 10, 3:02PM CST
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the fourth quarter of 2014.
THOR: 40.01 (+0.54)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Thoratec Up 20.0% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Mon Feb 09, 9:13AM CST
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 3 months, Thoratec has returned 20.03% as of today's recent price of $36.01.
THOR: 40.01 (+0.54)
Will Thoratec (THOR) Miss Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 3:42PM CST
Our proven model does not conclusively show that Thoratec Corp. (THOR) is likely to beat earnings this quarter.
ACT: 285.37 (+3.71), THOR: 40.01 (+0.54), INFI: 15.13 (+0.55), HLS: 45.01 (+0.30)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
If Thoratec's Woes Are Heartware's Gain, That's Disastrous For Both
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
An area of potential above average real growth This article is a continuation of my series looking at corporations with mechanical heart assist devices as part of a strategy for seeking above average returns by investing in heart health related...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Clinical Hold For Revive-IT Trial Raises Questions About Thoratec And Heartware
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
From the Revive-IT official web-site : REVIVE-IT is a two-part study consisting of a trial and a registry. The purpose of the REVIVE-IT study is to find out whether people with advanced heart failure who are not candidates for a heart transplant...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
